Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.

“The semaglutide molecule segment accounted for the largest share by molecule in 2023.”

In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.

“The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029.”

The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

Research Coverage:

This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).

Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

Tables List

Table 1 Oral Proteins & Peptides Market: Impact Analysis

Table 2 Oral Proteins & Peptides Market: Role Of Raw Material Vendors

Table 3 Oral Proteins & Peptides Market: Role Of Product Providers

Table 4 Oral Proteins & Peptides Market: Role Of End Users

Table 5 Oral Proteins & Peptides Market: Role Of Regulatory Authorities

Table 6 Oral Proteins & Peptides Market: Porter’s Five Forces Analysis

Table 7 Buying Criteria For Oral Proteins & Peptides, By End User

Table 8 Pricing Analysis, By Product, 2024

Table 9 Pricing Analysis, By Country And Region (Usd), 2024

Table 10 Regulatory Scenario For Oral Proteins & Peptides Market

Table 11 North America: List Of Regulatory Bodies, Government Agencies,

And Other Organizations

Table 12 Europe: List Of Regulatory Bodies, Government Agencies,

And Other Organizations

Table 13 Asia Pacific: List Of Regulatory Bodies, Government Agencies,

And Other Organizations

Table 14 Rest Of The World: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 15 Oral Peptides In Clinical Pipeline (As Of August 2024)

Table 16 Oral Proteins & Peptides Market: Top 20 Patent Owners, 2014–2024

Table 17 Indicative List Of Patents In Oral Proteins & Peptides Market,

2022–2024

Table 18 Oral Proteins & Peptides Market: Detailed List Of

Conferences & Events

Table 19 Oral Proteins & Peptides Market, By Molecule, 2022–2029 (Usd Million)

Table 20 Semaglutide Market, By Region, 2022–2029 (Usd Million)

Table 21 North America: Semaglutide Market, By Country,

2022–2029 (Usd Million)

Table 22 Europe: Semaglutide Market, By Country, 2022–2029 (Usd Million)

Table 23 Asia Pacific: Semaglutide Market, By Country, 2022–2029 (Usd Million)

Table 24 Latin America: Semaglutide Market, By Country,

2022–2029 (Usd Million)

Table 25 Middle East: Semaglutide Market, By Region, 2022–2029 (Usd Million)

Table 26 Gcc Countries: Semaglutide Market, By Country,

2022–2029 (Usd Million)

Table 27 Calcitonin Market, By Region, 2022–2029 (Usd Million)

Table 28 North America: Calcitonin Market, By Country, 2022–2029 (Usd Million)

Table 29 Europe: Calcitonin Market, By Country, 2022–2029 (Usd Million)

Table 30 Asia Pacific: Calcitonin Market, By Country, 2022–2029 (Usd Million)

Table 31 Latin America: Calcitonin Market, By Country, 2022–2029 (Usd Million)

Table 32 Middle East: Calcitonin Market, By Region, 2022–2029 (Usd Million)

Table 33 Gcc Countries: Calcitonin Market, By Country, 2022–2029 (Usd Million)

Table 34 Linaclotide Market, By Region, 2022–2029 (Usd Million)

Table 35 North America: Linaclotide Market, By Country,

2022–2029 (Usd Million)

Table 36 Europe: Linaclotide Market, By Country, 2022–2029 (Usd Million)

Table 37 Asia Pacific: Linaclotide Market, By Country, 2022–2029 (Usd Million)

Table 38 Latin America: Linaclotide Market, By Country, 2022–2029 (Usd Million)

Table 39 Middle East: Linaclotide Market, By Region, 2022–2029 (Usd Million)

Table 40 Gcc Countries: Linaclotide Market, By Country,

2022–2029 (Usd Million)

Table 41 Trofinetide Market, By Region, 2022–2029 (Usd Million)

Table 42 North America: Trofinetide Market, By Country,

2022–2029 (Usd Million)

Table 43 Europe: Trofinetide Market, By Country, 2022–2029 (Usd Million)

Table 44 Asia Pacific: Trofinetide Market, By Country, 2022–2029 (Usd Million)

Table 45 Latin America: Trofinetide Market, By Country, 2022–2029 (Usd Million)

Table 46 Middle East: Trofinetide Market, By Region, 2022–2029 (Usd Million)

Table 47 Gcc Countries: Trofinetide Market, By Country,

2022–2029 (Usd Million)

Table 48 Voclosporin Market, By Region, 2022–2029 (Usd Million)

Table 49 North America: Voclosporin Market, By Country,

2022–2029 (Usd Million)

Table 50 Europe: Voclosporin Market, By Country, 2022–2029 (Usd Million)

Table 51 Asia Pacific: Voclosporin Market, By Country, 2022–2029 (Usd Million)

Table 52 Plecanatide Market, By Region, 2022–2029 (Usd Million)

Table 53 North America: Plecanatide Market, By Country,

2022–2029 (Usd Million)

Table 54 Europe: Plecanatide Market, By Country, 2022–2029 (Usd Million)

Table 55 Asia Pacific: Plecanatide Market, By Country, 2022–2029 (Usd Million)

Table 56 Latin America: Plecanatide Market, By Country, 2022–2029 (Usd Million)

Table 57 Middle East: Plecanatide Market, By Region, 2022–2029 (Usd Million)

Table 58 Gcc Countries: Plecanatide Market, By Country,

2022–2029 (Usd Million)

Table 59 Other Oral Protein & Peptide Molecules Market, By Region,

2022–2029 (Usd Million)

Table 60 North America: Other Oral Protein & Peptide Molecules Market,

By Country, 2022–2029 (Usd Million)

Table 61 Europe: Other Oral Protein & Peptide Molecules Market,

By Country, 2022–2029 (Usd Million)

Table 62 Asia Pacific: Other Oral Protein & Peptide Molecules Market,

By Country, 2022–2029 (Usd Million)

Table 63 Latin America: Other Oral Protein & Peptide Molecules Market,

By Country, 2022–2029 (Usd Million)

Table 64 Middle East: Other Oral Protein & Peptide Molecules Market,

By Region, 2022–2029 (Usd Million)

Table 65 Gcc Countries: Other Oral Protein & Peptide Molecules Market,

By Country, 2022–2029 (Usd Million)

Table 66 Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 67 Glp-1 Receptor Agonists Market, By Region, 2022–2029 (Usd Million)

Table 68 North America: Glp-1 Receptor Agonists Market, By Country,

2022–2029 (Usd Million)

Table 69 Europe: Glp-1 Receptor Agonists Market, By Country,

2022–2029 (Usd Million)

Table 70 Asia Pacific: Glp-1 Receptor Agonists Market, By Country,

2022–2029 (Usd Million)

Table 71 Latin America: Glp-1 Receptor Agonists Market, By Country,

2022–2029 (Usd Million)

Table 72 Middle East: Glp-1 Receptor Agonists Market, By Region,

2022–2029 (Usd Million)

Table 73 Gcc Countries: Glp-1 Receptor Agonists Market, By Country,

2022–2029 (Usd Million)

Table 74 Cgrp Receptor Antagonists Market, By Region, 2022–2029 (Usd Million)

Table 75 North America: Cgrp Receptor Antagonists Market, By Country,

2022–2029 (Usd Million)

Table 76 Europe: Cgrp Receptor Antagonists Market, By Country,

2022–2029 (Usd Million)

Table 77 Asia Pacific: Cgrp Receptor Antagonists Market, By Country,

2022–2029 (Usd Million)

Table 78 Latin America: Cgrp Receptor Antagonists Market, By Country,

2022–2029 (Usd Million)

Table 79 Middle East: Cgrp Receptor Antagonists Market, By Region,

2022–2029 (Usd Million)

Table 80 Gcc Countries: Cgrp Receptor Antagonists Market, By Country,

2022–2029 (Usd Million)

Table 81 Gc-c Agonists Market, By Region, 2022–2029 (Usd Million)

Table 82 North America: Gc-c Agonists Market, By Country,

2022–2029 (Usd Million)

Table 83 Europe: Gc-c Agonists Market, By Country, 2022–2029 (Usd Million)

Table 84 Asia Pacific: Gc-c Agonists Market, By Country, 2022–2029 (Usd Million)

Table 85 Latin America: Gc-c Agonists Market, By Country,

2022–2029 (Usd Million)

Table 86 Middle East: Gc-c Agonists Market, By Region, 2022–2029 (Usd Million)

Table 87 Gcc Countries: Gc-c Agonists Market, By Country,

2022–2029 (Usd Million)

Table 88 Gpe Market, By Region, 2022–2029 (Usd Million)

Table 89 North America: Gpe Market, By Country, 2022–2029 (Usd Million)

Table 90 Europe: Gpe Market, By Country, 2022–2029 (Usd Million)

Table 91 Asia Pacific: Gpe Market, By Country, 2022–2029 (Usd Million)

Table 92 Latin America: Gpe Market, By Country, 2022–2029 (Usd Million)

Table 93 Middle East: Gpe Market, By Region, 2022–2029 (Usd Million)

Table 94 Gcc Countries: Gpe Market, By Country, 2022–2029 (Usd Million)

Table 95 Cni Market, By Region, 2022–2029 (Usd Million)

Table 96 North America: Cni Market, By Country, 2022–2029 (Usd Million)

Table 97 Europe: Cni Market, By Country, 2022–2029 (Usd Million)

Table 98 Asia Pacific: Cni Market, By Country, 2022–2029 (Usd Million)

Table 99 Other Oral Protein & Peptide Drug Classes Market,

By Region, 2022–2029 (Usd Million)

Table 100 North America: Other Oral Protein & Peptide Drug Classes Market,

By Country, 2022–2029 (Usd Million)

Table 101 Europe: Other Oral Protein & Peptide Drug Classes Market,

By Country, 2022–2029 (Usd Million)

Table 102 Asia Pacific: Other Oral Protein & Peptide Drug Classes Market,

By Country, 2022–2029 (Usd Million)

Table 103 Latin America: Other Oral Protein & Peptide Drug Classes Market,

By Country, 2022–2029 (Usd Million)

Table 104 Middle East: Other Oral Protein & Peptide Drug Classes Market,

By Region, 2022–2029 (Usd Million)

Table 105 Gcc Countries: Other Oral Protein & Peptide Drug Classes Market,

By Country, 2022–2029 (Usd Million)

Table 106 Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 107 Oral Proteins & Peptides Market For Diabetes, By Region,

2022–2029 (Usd Million)

Table 108 North America: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 109 Europe: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 110 Asia Pacific: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 111 Latin America: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 112 Middle East: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 113 Gcc Countries: Oral Proteins & Peptides Market For Diabetes,

By Country, 2022–2029 (Usd Million)

Table 114 Oral Proteins & Peptides Market For Cns Disorders, By Region,

2022–2029 (Usd Million)

Table 115 North America: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 116 Europe: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 117 Asia Pacific: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 118 Latin America: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 119 Middle East: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 120 Gcc Countries: Oral Proteins & Peptides Market For Cns Disorders,

By Country, 2022–2029 (Usd Million)

Table 121 Oral Proteins & Peptides Market For Gastroenterology,

By Region, 2022–2029 (Usd Million)

Table 122 North America: Oral Proteins & Peptides Market For Gastroenterology, By Country, 2022–2029 (Usd Million)

Table 123 Europe: Oral Proteins & Peptides Market For Gastroenterology,

By Country, 2022–2029 (Usd Million)

Table 124 Asia Pacific: Oral Proteins & Peptides Market For Gastroenterology,

By Country, 2022–2029 (Usd Million)

Table 125 Latin America: Oral Proteins & Peptides Market For Gastroenterology, By Country, 2022–2029 (Usd Million)

Table 126 Middle East: Oral Proteins & Peptides Market For Gastroenterology, By Country, 2022–2029 (Usd Million)

Table 127 Gcc Countries: Oral Proteins & Peptides Market For Gastroenterology, By Country, 2022–2029 (Usd Million)

Table 128 Oral Proteins & Peptides Market For Genetic Disorders, By Region, 2022–2029 (Usd Million)

Table 129 North America: Oral Proteins & Peptides Market For Genetic Disorders, By Country, 2022–2029 (Usd Million)

Table 130 Europe: Oral Proteins & Peptides Market For Genetic Disorders,

By Country, 2022–2029 (Usd Million)

Table 131 Asia Pacific: Oral Proteins & Peptides Market For Genetic Disorders,

By Country, 2022–2029 (Usd Million)

Table 132 Latin America: Oral Proteins & Peptides Market For Genetic Disorders, By Country, 2022–2029 (Usd Million)

Table 133 Middle East: Oral Proteins & Peptides Market For Genetic Disorders, By Region, 2022–2029 (Usd Million)

Table 134 Gcc Countries: Oral Proteins & Peptides Market For Genetic Disorders, By Country, 2022–2029 (Usd Million)

Table 135 Oral Proteins & Peptides Market For Nephrology, By Region,

2022–2029 (Usd Million)

Table 136 North America: Oral Proteins & Peptides Market For Nephrology,

By Country, 2022–2029 (Usd Million)

Table 137 Europe: Oral Proteins & Peptides Market For Nephrology,

By Country, 2022–2029 (Usd Million)

Table 138 Asia Pacific: Oral Proteins & Peptides Market For Nephrology,

By Country, 2022–2029 (Usd Million)

Table 139 Oral Proteins & Peptides Market For Obesity & Overweight, By Region, 2022–2029 (Usd Million)

Table 140 North America: Oral Proteins & Peptides Market For Obesity & Overweight, By Country, 2022–2029 (Usd Million)

Table 141 Europe: Oral Proteins & Peptides Market For Obesity & Overweight,

By Country, 2022–2029 (Usd Million)

Table 142 Asia Pacific: Oral Proteins & Peptides Market For Obesity & Overweight, By Country, 2022–2029 (Usd Million)

Table 143 Oral Proteins & Peptides Market For Other Therapeutic Areas,

By Region, 2022–2029 (Usd Million)

Table 144 North America: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 145 Europe: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 146 Asia Pacific: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 147 Latin America: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 148 Middle East: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 149 Gcc Countries: Oral Proteins & Peptides Market For Other Therapeutic Areas, By Country, 2022–2029 (Usd Million)

Table 150 Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 151 Oral Protein & Peptide Tablets Market, By Region,

2022–2029 (Usd Million)

Table 152 North America: Oral Protein & Peptide Tablets Market,

By Country, 2022–2029 (Usd Million)

Table 153 Europe: Oral Protein & Peptide Tablets Market, By Country,

2022–2029 (Usd Million)

Table 154 Asia Pacific: Oral Protein & Peptide Tablets Market, By Country,

2022–2029 (Usd Million)

Table 155 Latin America: Oral Protein & Peptide Tablets Market, By Country, 2022–2029 (Usd Million)

Table 156 Middle East: Oral Protein & Peptide Tablets Market, By Country,

2022–2029 (Usd Million)

Table 157 Gcc Countries: Oral Protein & Peptide Tablets Market, By Country, 2022–2029 (Usd Million)

Table 158 Oral Protein & Peptide Capsules Market, By Region,

2022–2029 (Usd Million)

Table 159 North America: Oral Protein & Peptide Capsules Market,

By Country, 2022–2029 (Usd Million)

Table 160 Europe: Oral Protein & Peptide Capsules Market, By Country,

2022–2029 (Usd Million)

Table 161 Asia Pacific: Oral Protein & Peptide Capsules Market, By Country,

2022–2029 (Usd Million)

Table 162 Latin America: Oral Protein & Peptide Capsules Market,

By Country, 2022–2029 (Usd Million)

Table 163 Middle East: Oral Protein & Peptide Capsules Market,

By Country, 2022–2029 (Usd Million)

Table 164 Gcc Countries: Oral Protein & Peptide Capsules Market,

By Country, 2022–2029 (Usd Million)

Table 165 Oral Protein & Peptide Solutions Market, By Region,

2022–2029 (Usd Million)

Table 166 North America: Oral Protein & Peptide Solutions Market,

By Country, 2022–2029 (Usd Million)

Table 167 Europe: Oral Protein & Peptide Solutions Market, By Country,

2022–2029 (Usd Million)

Table 168 Asia Pacific: Oral Protein & Peptide Solutions Market,

By Country, 2022–2029 (Usd Million)

Table 169 Latin America: Oral Protein & Peptide Solutions Market,

By Country, 2022–2029 (Usd Million)

Table 170 Middle East: Oral Protein & Peptide Solutions Market,

By Country, 2022–2029 (Usd Million)

Table 171 Gcc Countries: Oral Protein & Peptide Solutions Market,

By Country, 2022–2029 (Usd Million)

Table 172 Oral Proteins & Peptides Market, By End User, 2022–2029 (Usd Million)

Table 173 Oral Proteins & Peptides Market For Home Care Settings,

By Region, 2022–2029 (Usd Million)

Table 174 North America: Oral Proteins & Peptides Market For Home Care Settings, By Country, 2022–2029 (Usd Million)

Table 175 Europe: Oral Proteins & Peptides Market For Home Care Settings,

By Country, 2022–2029 (Usd Million)

Table 176 Asia Pacific: Oral Proteins & Peptides Market For Home

Care Settings, By Country, 2022–2029 (Usd Million)

Table 177 Latin America: Oral Proteins & Peptides Market For Home Care Settings, By Country, 2022–2029 (Usd Million)

Table 178 Middle East: Oral Proteins & Peptides Market For Home Care Settings, By Region, 2022–2029 (Usd Million)

Table 179 Gcc Countries: Oral Proteins & Peptides Market For Home Care Settings, By Country, 2022–2029 (Usd Million)

Table 180 Oral Proteins & Peptides Market For Long-term Care Facilities,

By Region, 2022–2029 (Usd Million)

Table 181 North America: Oral Proteins & Peptides Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 182 Europe: Oral Proteins & Peptides Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 183 Asia Pacific: Oral Proteins & Peptides Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 184 Latin America: Oral Proteins & Peptides Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 185 Middle East: Oral Proteins & Peptides Market For Long-term Care Facilities, By Region, 2022–2029 (Usd Million)

Table 186 Gcc Countries: Oral Proteins & Peptides Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 187 Oral Proteins & Peptides Market For Hospitals & Specialty Clinics,

By Region, 2022–2029 (Usd Million)

Table 188 North America: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Country, 2022–2029 (Usd Million)

Table 189 Europe: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Country, 2022–2029 (Usd Million)

Table 190 Asia Pacific: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Country, 2022–2029 (Usd Million)

Table 191 Latin America: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Country, 2022–2029 (Usd Million)

Table 192 Middle East: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Region, 2022–2029 (Usd Million)

Table 193 Gcc Countries: Oral Proteins & Peptides Market For Hospitals & Specialty Clinics, By Country, 2022–2029 (Usd Million)

Table 194 Oral Proteins & Peptides Market, By Region, 2022–2029 (Usd Million)

Table 195 North America: Macroeconomic Outlook

Table 196 North America: Oral Proteins & Peptides Market, By Country,

2022–2029 (Usd Million)

Table 197 North America: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 198 North America: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 199 North America: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 200 North America: Oral Proteins & Peptides Market, By Formulation, 2022–2029 (Usd Million)

Table 201 North America: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 202 Us: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 203 Us: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 204 Us: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 205 Us: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 206 Us: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 207 Canada: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 208 Canada: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 209 Canada: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 210 Canada: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 211 Canada: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 212 Europe: Macroeconomic Outlook

Table 213 Europe: Oral Proteins & Peptides Market, By Country,

2022–2029 (Usd Million)

Table 214 Europe: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 215 Europe: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 216 Europe: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 217 Europe: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 218 Europe: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 219 Germany: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 220 Germany: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 221 Germany: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 222 Germany: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 223 Germany: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 224 Uk: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 225 Uk: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 226 Uk: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 227 Uk: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 228 Uk: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 229 France: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 230 France: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 231 France: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 232 France: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 233 France: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 234 Italy: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 235 Italy: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 236 Italy: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 237 Italy: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 238 Italy: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 239 Spain: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 240 Spain: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 241 Spain: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 242 Spain: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 243 Spain: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 244 Netherlands: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 245 Netherlands: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 246 Netherlands: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 247 Netherlands: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 248 Netherlands: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 249 Rest Of Europe: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 250 Rest Of Europe: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 251 Rest Of Europe: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 252 Rest Of Europe: Oral Proteins & Peptides Market, By Formulation, 2022–2029 (Usd Million)

Table 253 Rest Of Europe: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 254 Asia Pacific: Macroeconomic Outlook

Table 255 Asia Pacific: Oral Proteins & Peptides Market, By Country,

2022–2029 (Usd Million)

Table 256 Asia Pacific: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 257 Asia Pacific: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 258 Asia Pacific: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 259 Asia Pacific: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 260 Asia Pacific: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 261 China: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 262 China: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 263 China: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 264 China: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 265 China: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 266 Japan: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 267 Japan: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 268 Japan: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 269 Japan: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 270 Japan: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 271 India: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 272 India: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 273 India: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 274 India: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 275 India: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 276 Australia: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 277 Australia: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 278 Australia: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 279 Australia: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 280 Australia: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 281 South Korea: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 282 South Korea: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 283 South Korea: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 284 South Korea: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 285 South Korea: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 286 Rest Of Asia Pacific: Oral Proteins & Peptides Market,

By Molecule, 2022–2029 (Usd Million)

Table 287 Rest Of Asia Pacific: Oral Proteins & Peptides Market,

By Drug Class, 2022–2029 (Usd Million)

Table 288 Rest Of Asia Pacific: Oral Proteins & Peptides Market,

By Therapeutic Area, 2022–2029 (Usd Million)

Table 289 Rest Of Asia Pacific: Oral Proteins & Peptides Market,

By Formulation, 2022–2029 (Usd Million)

Table 290 Rest Of Asia Pacific: Oral Proteins & Peptides Market,

By End User, 2022–2029 (Usd Million)

Table 291 Latin America: Macroeconomic Outlook

Table 292 Latin America: Oral Proteins & Peptides Market, By Country,

2022–2029 (Usd Million)

Table 293 Latin America: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 294 Latin America: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 295 Latin America: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 296 Latin America: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 297 Latin America: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 298 Brazil: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 299 Brazil: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 300 Brazil: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 301 Brazil: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 302 Brazil: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 303 Mexico: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 304 Mexico: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 305 Mexico: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 306 Mexico: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 307 Mexico: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 308 Rest Of Latin America: Oral Proteins & Peptides Market,

By Molecule, 2022–2029 (Usd Million)

Table 309 Rest Of Latin America: Oral Proteins & Peptides Market,

By Drug Class, 2022–2029 (Usd Million)

Table 310 Rest Of Latin America: Oral Proteins & Peptides Market,

By Therapeutic Area, 2022–2029 (Usd Million)

Table 3 11 Rest Of Latin America: Oral Proteins & Peptides Market,

By Formulation, 2022–2029 (Usd Million)

Table 312 Rest Of Latin America: Oral Proteins & Peptides Market,

By End User, 2022–2029 (Usd Million)

Table 313 Middle East: Macroeconomic Outlook

Table 314 Middle East: Oral Proteins & Peptides Market, By Country,

2022–2029 (Usd Million)

Table 315 Middle East: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 316 Middle East: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 317 Middle East: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 318 Middle East: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 319 Middle East: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 320 Gcc Countries: Oral Proteins & Peptides Market, By Region,

2022–2029 (Usd Million)

Table 321 Gcc Countries: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 322 Gcc Countries: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 323 Gcc Countries: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 324 Gcc Countries: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 325 Gcc Countries: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 326 Saudi Arabia: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 327 Saudi Arabia: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 328 Saudi Arabia: Oral Proteins & Peptides Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 329 Saudi Arabia: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 330 Saudi Arabia: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 331 Uae: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 332 Uae: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 333 Uae: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 334 Uae: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 335 Uae: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 336 Rest Of Gcc Countries: Oral Proteins & Peptides Market,

By Molecule, 2022–2029 (Usd Million)

Table 337 Rest Of Gcc Countries: Oral Proteins & Peptides Market,

By Drug Class, 2022–2029 (Usd Million)

Table 338 Rest Of Gcc Countries: Oral Proteins & Peptides Market,

By Therapeutic Area, 2022–2029 (Usd Million)

Table 339 Rest Of Gcc Countries: Oral Proteins & Peptides Market,

By Formulation, 2022–2029 (Usd Million)

Table 340 Rest Of Gcc Countries: Oral Proteins & Peptides Market,

By End User, 2022–2029 (Usd Million)

Table 341 Rest Of Middle East: Oral Proteins & Peptides Market,

By Molecule, 2022–2029 (Usd Million)

Table 342 Rest Of Middle East: Oral Proteins & Peptides Market,

By Drug Class, 2022–2029 (Usd Million)

Table 343 Rest Of Middle East: Oral Proteins & Peptides Market,

By Therapeutic Area, 2022–2029 (Usd Million)

Table 344 Rest Of Middle East: Oral Proteins & Peptides Market,

By Formulation, 2022–2029 (Usd Million)

Table 345 Rest Of Middle East: Oral Proteins & Peptides Market,

By End User, 2022–2029 (Usd Million)

Table 346 Africa: Macroeconomic Outlook

Table 347 Africa: Oral Proteins & Peptides Market, By Molecule,

2022–2029 (Usd Million)

Table 348 Africa: Oral Proteins & Peptides Market, By Drug Class,

2022–2029 (Usd Million)

Table 349 Africa: Oral Proteins & Peptides Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 350 Africa: Oral Proteins & Peptides Market, By Formulation,

2022–2029 (Usd Million)

Table 351 Africa: Oral Proteins & Peptides Market, By End User,

2022–2029 (Usd Million)

Table 352 Overview Of Strategies Deployed By Key Players In Oral

Proteins & Peptides Market

Table 353 Oral Proteins & Peptides Market: Degree Of Competition

Table 354 Oral Proteins & Peptides Market: Molecule Footprint (Key Players)

Table 355 Oral Proteins & Peptides Market: Formulation Footprint (Key Players)

Table 356 Oral Proteins & Peptides Market: Therapeutic Area Footprint

(Key Players)

Table 357 Oral Proteins & Peptides Market: Therapeutic Area Footprint

(Players With Products In Pipeline)

Table 358 Oral Proteins & Peptides Market: Region Footprint (Key Players)

Table 359 Oral Proteins & Peptides Market: Region Footprint

(Players With Products In Pipeline)

Table 360 Oral Proteins & Peptides Market: Key Startups/Smes

Table 361 Oral Proteins & Peptides Market: Competitive Benchmarking

Of Key Emerging Players/Startups

Table 362 Oral Proteins & Peptides Market: Product Approvals,

January 2021– August 2024

Table 363 Oral Proteins & Peptides Market: Deals, January 2021–august 2024

Table 364 Oral Proteins & Peptides Market: Expansions, January 2021–

August 2024

Table 365 Oral Proteins & Peptides Market: Other Developments,

January 2021– August 2024

Table 366 Novo Nordisk: Company Overview

Table 367 Novo Nordisk: Products Offered

Table 368 Novo Nordisk: Product Launches & Approvals, January 2021–

August 2024

Table 369 Novo Nordisk: Expansions, January 2021– August 2024

Table 370 Novo Nordisk: Other Developments, January 2021– August 2024

Table 371 Abbvie: Company Overview

Table 372 Abbvie: Products Offered

Table 373 Abbvie: Product Approvals, January 2021– August 2024

Table 374 Pfizer: Company Overview

Table 375 Pfizer: Product Pipeline

Table 376 Pfizer: Product Approvals, January 2021–august 2024

Table 377 Pfizer: Deals, January 2021–august 2024

Table 378 Pfizer: Other Developments, January 2021–august 2024

Table 379 Bausch Health Companies: Company Overview

Table 380 Bausch Health Companies: Products Offered

Table 381 Bausch Health Companies: Product Approvals, January 2021–

August 2024

Table 382 Chiesi Farmaceutici: Company Overview

Table 383 Chiesi Farmaceutici: Products Offered

Table 384 Chiesi Farmaceutici: Deals, January 2021–august 2024

Table 385 Acadia Pharmaceuticals: Company Overview

Table 386 Acadia Pharmaceuticals: Products Offered

Table 387 Acadia Pharmaceuticals: Product Approvals, January 2021–

August 2024

Table 388 Aurinia Pharmaceuticals: Company Overview

Table 389 Aurinia Pharmaceuticals: Products Offered

Table 390 Aurinia Pharmaceuticals: Product Approvals, January 2021–

August 2024

Table 391 Merck & Co.: Company Overview

Table 392 Merck & Co.: Product Pipeline

Table 393 Merck & Co.: Other Developments, January 2021–august 2024

Table 394 Johnson & Johnson Services: Company Overview

Table 395 Johnson & Johnson Services: Product Pipeline

Table 396 Johnson & Johnson Services: Other Developments, January 2021– August 2024

Table 397 Swk Holdings: Company Overview

Table 398 Swk Holdings: Product Pipeline

Table 399 Swk Holdings: Other Developments, January 2021–august 2024

Table 400 R-pharm Jsc: Company Overview

Table 401 R-pharm Jsc: Products In Pipeline

Table 402 Entera Bio: Company Overview

Table 403 Entera Bio: Product Pipeline

Table 404 Entera Bio: Deals, January 2021–august 2024

Table 405 Entera Bio: Other Developments, January 2021–august 2024

Table 406 Proxima Concepts: Company Overview

Table 407 Proxima Concepts: Products In Pipeline

Figures List

Figure 1 Research Design

Figure 2 Breakdown Of Primaries: Supply And Demand-side Participants

Figure 3 Market Size Estimation: Supply-side Analysis, 2023

Figure 4 Market Size Estimation: Approach 1 (Revenue Share Analysis), 2023

Figure 5 Market Validation From Primary Experts

Figure 6 Market Size Estimation: Bottom-up Approach

Figure 7 Cagr Projections: Oral Proteins & Peptides Market, 2024–2029

Figure 8 Impact Analysis Of Drivers, Restraints, Opportunities, And Challenges In Oral Proteins & Peptides Market

Figure 9 Data Triangulation Methodology

Figure 10 Oral Proteins & Peptides Market, By Molecule,

2024 Vs. 2029 (Usd Million)

Figure 11 Oral Proteins & Peptides Market Share, By Drug Class,

2024 Vs. 2029 (Usd Million)

Figure 12 Oral Proteins & Peptides Market Share, By Therapeutic Area,

2024 Vs. 2029 (Usd Million)

Figure 13 Oral Proteins & Peptides Market Share, By Formulation,

2024 Vs. 2029 (Usd Million)

Figure 14 Oral Proteins & Peptides Market, By End User,

2024 Vs. 2029 (Usd Million)

Figure 15 Geographical Snapshot Of Oral Proteins & Peptides Market

Figure 16 Increasing Approvals Of Oral Protein & Peptide Drugs

To Drive Market Growth

Figure 17 Tablets Accounted For Largest Share Of North American

Market In 2023

Figure 18 Diabetes Accounted For Largest Market Share In 2023

Figure 19 Home Care Settings To Dominate Market Till 2029

Figure 20 China To Register Highest Growth During Forecast Period

Figure 21 Oral Proteins & Peptides Market: Drivers, Restraints,

Opportunities, And Challenges

Figure 22 Oral Proteins & Peptides Market: Ecosystem Analysis

Figure 23 Oral Proteins & Peptides Market: Value Chain Analysis

Figure 24 Oral Proteins & Peptides Market: Supply Chain Analysis

Figure 25 Oral Proteins & Peptides Market: Porter’s Five Forces Analysis

Figure 26 Influence Of Stakeholders In Buying Process Of Oral Proteins & Peptides

Figure 27 Key Buying Criteria For End Users

Figure 28 Trends/Disruptions Impacting Customers’ Businesses

Figure 29 Total Number Of Patents Granted, 2014–2024

Figure 30 Top Ten Players With Highest Number Of Patent Applications,

2014–2024

Figure 31 Oral Proteins & Peptides Market: Investment & Funding Scenario

Figure 32 North America Oral Proteins & Peptides Market Snapshot

Figure 33 Europe: Oral Proteins & Peptides Market Snapshot

Figure 34 Revenue Analysis Of Key Players In Oral Proteins & Peptides

Market, 2021–2023 (Usd Million)

Figure 35 Market Share Analysis Of Key Players In Oral Proteins & Peptides (2023)

Figure 36 Oral Proteins & Peptides Market: Company Evaluation Matrix

(Key Players), 2023

Figure 37 Oral Proteins & Peptides Market: Company Evaluation Matrix (Players With Products In Pipeline), 2023

Figure 38 Oral Proteins & Peptides Market: Company Footprint (Key Players)

Figure 39 Oral Proteins & Peptides Market: Company Footprint (Players With Products In Pipeline)

Figure 40 Oral Proteins & Peptides Market: Company Evaluation Matrix (Startups/Smes), 2023

Figure 41 Ev/Ebitda Of Key Vendors

Figure 42 Year-to-date (Ytd) Price Total Return And 5-year Stock

Beta Of Key Vendors

Figure 43 Oral Proteins & Peptides Market: Brand/Product Comparative Analysis

Figure 44 Novo Nordisk: Company Snapshot

Figure 45 Abbvie: Company Snapshot

Figure 46 Pfizer: Company Snapshot

Figure 47 Bausch Health Companies: Company Snapshot

Figure 48 Chiesi Farmaceutici: Company Snapshot

Figure 49 Acadia Pharmaceuticals: Company Snapshot

Figure 50 Aurinia Pharmaceuticals: Company Snapshot

Figure 51 Merck & Co.: Company Snapshot

Figure 52 Johnson & Johnson Services: Company Snapshot

Figure 53 Swk Holdings: Company Snapshot